Similar companies
| Company | Stocktwits Subscribers | |
|---|---|---|
 |
Gilead SciencesGILD |
77,672 0% |
 |
Inovio PharmaceuticalsINO |
93,048 0% |
 |
Anavex Life SciencesAVXL |
22,910 0% |
 |
BridgeBio PharmaBBIO |
5,101 0% |
 |
Editas MedicineEDIT |
17,182 0% |
Month over Month
Subscribing Stocktwits Users
| Mar 2025 | 6,617 | |
| Feb 2025 | 6,583 | |
| Jan 2025 | 6,544 | |
| Dec 2024 | 6,535 | |
| Nov 2024 | 6,525 |
How many users are following Novartis on StockTwits?
The interest in Novartis on StockTwits is minor, with a following of 6,279 investors.
Analyzing Stocktwits Subscribers, how is Novartis performing compared to its industry peers?
Novartis underperforms its industry peers when it comes to Stocktwits Subscribers, ranking in the 4th percentile.
What has been the change in Novartis' StockTwits followers over the past month?
The number of followers for Novartis on StockTwits has risen by 0.3% in the last month, indicating a growing interest or optimism among investors. For investors, this upward trend in follower count is an important indicator to consider, as it may reflect broader market sentiments and could have implications for Novartis' price performance.
What is StockTwits?
StockTwits is a social media platform designed specifically for the investing community. It enables investors and traders to share market insights, strategies, and real-time news updates. Essentially, it's a specialized network for financial market discussions, often characterized by brief, tweet-like posts.
Why is it important for Novartis investors to monitor its StockTwits followers?
For investors in Novartis, tracking the number of followers on StockTwits can be highly beneficial. The platform's follower count offers a direct gauge of investor interest and sentiment surrounding Ford. An increasing follower count typically suggests growing investor attention and can be an indicator of rising market enthusiasm or concern about the company's prospects. This data can provide investors with valuable insights into market trends, potential shifts in investor behavior, and broader perceptions of Ford in the investment community.
Sign up and get more insights on Novartis.
